S-1 Plus Carboplatin May Be Effective in NSCLC Patients With Interstitial Lung Disease

Patients with severe complications, such as interstitial lung disease, are often excluded from clinical studies assessing chemotherapy in NSCLC.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2p3QxL5